Please Wait...

PTH, Intact // Intact Parathyroid Hormone

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

PTH is produced in the parathyroid gland and is a key regulator in skeletal and mineral homeostasis. PTH is a 84 amino-acid peptide, with an helical conformation in the 1-34 portion of its binding domain to its receptor of type 1 (PTH1R) (Jin et al., 2000). PTH and PTH-related peptide (PTHrP) have highly conserved sequences and activates PTH1R. The C terminal fragments of the intact PTH, PTH(39-84) or PTH(53-84) bind another receptor CPTHR, expressed on bone cells (Divieti et al., 2001). The 1-34 portion of PTH (and the PTHrP) stimulate bone formation and increase bone mass in patients with osteoporosis (Brommage et al., 1999; Lindsay et al., 1997). On the opposite, the truncated PTH 7-34 is a low affinity agonist of the receptor PTHR1 with the C terminus part required for the high affinity binding to the receptor (Gardella et al., 1991; Jin et al., 2000). Since PTH circulates under different forms, biologically active or not, immunoassays for its measurement must be chosen with particular attention (Komaba et al., 2009; Souberbielle et al., 2006).

Several automated or manual sandwich immunoassays are employed in the laboratory for measurement in plasma and/or serum:

  • Second generation assays designed to measure the entire 1-84 amino-acid peptide in addition to the 7-84 amino-acid peptide (Intact PTH or Total PTH),
  • "Third" generation assays which measure only the 1-84 amino-acid peptide (Whole PTH or biologically active PTH) and the Amino-PTH (a post-translational form produced in parathyroid carcinomas).


Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Still time to catch up on summer reading on recent developments in #Alzheimer's Disease Fluid Biomarkers here int t…
bioclinica (Yesterday)
Our clients have substantial success w #eSource, some spanning well over a decade. Still other organizations remain…
bioclinica (2 days ago)
Our clients have substantial success w #eSource, some spanning well over a decade. Still some in the industry remai…
bioclinica (4 days ago)
RT @RfwrightLSL: When Do You Think #BYOD (Bring Your Own Device) Will Become Widely Used To Capture PRO Data In #Clinical #Research? https:…
bioclinica (1 week ago)
ICYMI: Our V.P./Head of Neuroscience & Cardiovascular Svcs., Dr. Joyce Suhy, talks about challenges in determining…
bioclinica (1 week ago)
RT @FCR_News_Today: FDA Issues New Guides on Use of Electronic Health Information in #ClinicalTrials. #ClinicalResearch…
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen